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Abstract
Introduction With the increased use of neoadjuvant therapy for breast cancer, there is a need for pre-operative prediction 
of prognosis. We aimed to assess the prognostic value of tumour stiffness measured by ultrasound shear wave elastography 
(SWE).
Methods A consecutive cohort of patients with invasive breast cancer underwent breast ultrasound (US) including SWE. 
The following were recorded prospectively: US diameter, stiffness at SWE, presentation source, core biopsy grade, oestrogen 
receptor (ER) status and pre-operative nodal status. Breast cancer-specific survival (BCSS) was analysed with regard to US 
size and stiffness, tumour grade on core biopsy, ER status, presentation mode and pre-operative nodal status. Analysis used 
Cox proportional hazards regression.
Results Of the 520 patients, 42 breast cancer and 53 non-breast cancer deaths were recorded at mean follow-up of 5.4 years. 
Hazard ratios (HR) for tertiles of stiffness were 1, 4.8 and 8.1 (P = 0.0001). HR for 2 groups based on US size < or ≥ 20 mm 
were 1 and 5.1 (P < 0.0001). HR for each unit increase in tumour grade on core biopsy was 3.9 (P < 0.0001). The HR for 
ER positivity compared to ER negativity was 0.21 (P < 0.001). BCSS was also associated with presentation mode and pre-
operative nodal status. In a multivariable model, stiffness, US size and ER status were independently associated with BCSS.
Conclusion Multiple pre-operative factors including stromal stiffness at SWE have independent prognostic significance. 
A larger dataset with longer follow-up could be used in the future to construct a pre-operative prognostic model to guide 
treatment decisions.
Keywords Breast cancer · Prognosis · Shear wave elastography · Ultrasound · Neoadjuvant chemotherapy
Introduction
The assessment of prognosis has traditionally been per-
formed after surgical excision of breast cancer using the 
classical prognostic factors of invasive tumour size, lymph 
node status, histological grade and vascular invasion status 
[1]. These prognostic factors are then used to guide deci-
sions regarding adjuvant systemic therapy. In recent years, 
the immunophenotype [2] and molecular phenotype [3] have 
also been used to inform these decisions. Online resources, 
such as Predict, are also widely used to give information 
on overall survival and the possible benefits of adjuvant 
therapy. However, with the increased use of neoadjuvant 
chemotherapy (NACT) there is a need for accurate pre-
operative prediction of prognosis to aid treatment selection. 
Pre-operatively, tumour size can be estimated from imaging 
and histological grade and ER and HER-2 status determined 
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from the core biopsy [4]. Mode of presentation (through 
mammographic screening or symptoms) has also been 
shown to affect outcome even when adjusted for pathological 
variables such as invasive tumour size and nodal status [5]. 
Ultrasound of the axilla with biopsy of abnormal nodes is 
diagnostic for approximately 50% of node-positive patients 
[6]. However, given the debate regarding the need for clear-
ance of all positive axillae, vigorous efforts to diagnose 
every positive axilla pre-operatively are being discouraged 
by some surgeons [7]. There is, therefore, a need for more 
reliable tools for the pre-operative assessment of prognosis.
The tumour microenvironment greatly contributes to can-
cer growth, dissemination and drug resistance. One of the 
key features involved in these functions is the extracellular 
matrix (ECM) remodelling. This process is characterised by 
an increased number of stromal cells, an increased secretion 
of extracellular matrix proteins as well as thickening and 
reorganization of the collagen fibrils which results in stiffen-
ing of the stroma [8]. A biophysical and histological study 
has shown that stromal stiffness is higher at the invasive 
front of the most aggressive breast tumours (HER2 ampli-
fied and triple-negative breast cancer, TNBC) compared to 
the less aggressive luminal tumours, suggesting an associa-
tion between stiff stroma and cancer aggression [9]. Conklin 
et al. have correlated collagen fibril orientation with poor 
survival regardless of tumour grade, size, node status and 
tumour subtype in breast cancer [10]. In vitro studies have 
demonstrated that substrate stiffness mediates drug resist-
ance in breast cancer cell lines [11]. In the neoadjuvant set-
ting, a stromal gene signature enriched in ECM protein was 
found to be associated with poor response to 5-fluorouracil, 
epirubicin and cyclophosphamide treatment [12]. All these 
findings led us to investigate stromal stiffness measured by 
shear wave elastography (SWE) as a prognostic marker of 
breast cancer survival. Shear wave elastography (SWE) is an 
ultrasound imaging method which allows quantification of 
lesional and peri-lesional stiffness and it has been shown to 
aid benign/malignant differentiation of breast masses [13]. 
SWE is highly reproducible and quantitative [14]. Both stiff-
ness at SWE and strain elastography have been shown to 
be predictors of nodal metastasis, independent of invasive 
tumour size, histological grade and vascular invasion status 
[15, 16]. Stiffness at SWE has a strong relationship with 
invasive tumour size, histological grade and poor outcome 
immunophenotypes [17, 18]. Stiffness at elastography has 
also been shown, in some studies, to be associated with 
chemotherapy resistance [19–21].
We therefore postulated that stiffness at SWE may be 
related to the prognosis of women with breast cancer. No 
previous studies have addressed this question. The aim of 
the study is to investigate associations between prospectively 
collected pre-operative factors (including stromal stiffness) 
and breast cancer survival in a consecutive cohort of women 
diagnosed with ultrasound visible, invasive breast cancer.
Methods
SWE, US, source of referral and histopathological details 
(including core biopsy grade, ER, HER-2 status and pre-
operative nodal status) were collected prospectively from a 
consecutive series of patients undergoing diagnostic breast 
examination for lesions subsequently shown to be invasive 
breast cancer (n = 540). Between April 2010 and January 
2013, all women had their US lesion diameter and mean 
stiffness (kPa) at SWE recorded irrespective of subsequent 
treatment (primary surgery, neoadjuvant systemic therapy 
and primary endocrine therapy). The core biopsy grade was 
recorded to allow inclusion of this parameter in assessment 
of prognosis pre-operatively. ER status and HER-2 status 
are routinely measured in our institution on the core biopsy 
rather than the surgical resection specimen in line with cur-
rent guidelines. All women had axillary US and core biopsy 
of abnormal nodes (cortex > 2.3 mm) for assessment of 
nodal status.
All US scans were performed by one of five breast radi-
ologists or an advanced radiography practitioner trained to 
perform and interpret breast ultrasound. These practitioners 
had between 7 and 22 years of breast ultrasound experience 
and had at least 12 months of experience performing SWE 
of solid breast lesions. Four SWE images in two orthogonal 
planes were obtained. The region of interest (ROI) utilized 
in all cases was 2 mm in diameter. Mean stiffness in kPa 
was taken as the average of the values taken from four SWE 
images taken in two orthogonal planes. The maximum US 
diameter used in the analysis was the largest obtained in 
any of the three planes. All scans were performed using an 
Aixplorer® ultrasound system (SuperSonic Imagine, Aix 
en Provence, France). Institutional Review Board ethical 
approval was waived for this retrospective analysis of pro-
spectively recorded data and all patients gave permission for 
evaluation of their images.
Patient’s survival including cause of death was ascer-
tained from local paper and electronic health records and 
the National Cancer Registry. Patients that died after devel-
oping metastatic breast cancer were assumed to have died 
of breast cancer. A total of 20 patients were excluded from 
the analysis on the following grounds: Twelve patients with 
metastases at presentation; five where cause of death could 
not be ascertained; two with no follow-up data; and one with 
a history of a previous breast cancer.
BCSS was assessed using Kaplan–Meier survival 
curves. Association between putative prognostic vari-
ables and BCSS was evaluated using Cox proportional 
hazards regression. Variables included in Cox models 
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were mean stiffness, tumour size, tumour grade, ER sta-
tus, presentation source (screening or symptomatic) and 
pre-operative nodal status. Mean stiffness was categorized 
into three equal size groups and size into two groups (< 20 
or ≥ 20 mm).
Results
After the 20 exclusions detailed above, 520 patients con-
stituted the study group (mean age 62 years, median age 
62 years and range 28–95 years). Two hundred and five 
(39%) patients had their cancer diagnosed at mammographic 
screening while 315 (61%) women had symptomatic can-
cers. The pathological characteristics of the tumours are 
shown in Table 1. Four hundred and twenty-one women 
underwent immediate surgery and surgical nodal staging of 
whom 42% had invasive cancers ≥ 20 mm in size and 29% 
had axillary macro-metastases. Of the remaining 99, four 
women had immediate surgery but did not undergo nodal 
staging. Forty-five women were treated with NACT and 11 
had neoadjuvant endocrine therapy. Thirty-nine women were 
treated using primary endocrine therapy due to severe co-
morbidities. The mean follow-up in women still alive at the 
time of reporting was 5.4 years.
Forty-two women of the 520 died of breast cancer (8%) 
while 53 women had non-breast cancer deaths (10%) during 
the follow-up period. Kaplan–Meier survival curves for three 
equal size groups based on stiffness are shown in Fig. 1 and 
curves by US size in Fig. 2. Kaplan–Meier survival curves 
according to core biopsy grade are shown in Fig. 3.
All variables except HER-2 were significantly associated 
with BCSS in univariable Cox regression models (Table 2). 
However, in a multivariable model, grade and mode of detec-
tion were no longer significant at a nominal P < 0.1 and these 
Table 1  Pathological and immunohistochemical characteristics of 
study cancers
As not all patients had immediate surgery denominators for vascular 
invasion, nodal status and invasive size vary
Histological grade 1 60 (12%)
Histological grade 2 225 (43%)
Histological grade 3 235 (45%)
Ductal carcinoma of no specific type 399 (77%)
Lobular cancer 65 (13%)
Tubular cancer 19 (4%)
< 10 mm 57 (13%)
10–20 mm 189 (44%)
21–30 mm 103 (24%)
> 30 mm 76 (18%)
Vascular invasion 108 (25%)
Node positive (macro-metastases) 122 (29%)
ER positive 429 (83%)
PR positive 373 (72%)
HER-2 positive 63 (12%)
Fig. 1  Kaplan-Meier survival 
curves for three equal size 
groups based on stiffness at 
shear wave elastography
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variables were excluded from the final multivariable model 
(Table 2). In this model, stiffness was strongly associated with 
BCSS (tertile 2 vs tertile 1 HR = 3.4, 95% CI 0.95–12 and 
tertile 3 vs tertile 1 HR = 4.7, 95% CI 1.4–16).
Fig. 2  Kaplan-Meier survival 
curves according to ultrasound 
size
Fig. 3  Kaplan-Meier survival 
curves according to core biopsy 
estimated histological grade
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Discussion
We have shown that US size, SWE stiffness, ER status and 
pre-operative nodal status are independent pre-operative 
predictors of prognosis in invasive breast cancer. The other 
pre-operative factors studied (core grade, and presentation) 
failed to reach statistical significance at multivariate analy-
sis but given the small number of events (n = 42) this could 
reflect the limited power of the study rather than true lack 
of effect.
If these factors are shown to be prognostic in larger and 
independent datasets, then a pre-operative prognostic model 
could be constructed and validated in the future. Such a pre-
operative prognostic model could also be used to guide clini-
cal decisions such as the appropriateness of NACT. Current 
prognostic models such as the NPI [22] and PREDICT use 
post-operative factors so cannot be used pre-operatively.
Grey scale US is used globally to evaluate breast masses, 
while SWE has gained use in recent years, and is now avail-
able from many leading equipment manufacturers. Perform-
ing SWE takes about 2 min per patient and reading the stiff-
ness from the acquired images also takes 2 min per patient 
[23]. In this study, we used Emean measurements but Emax 
measurement give equally good results in studies of benign/
malignant differentiation [24]. Including SWE in the routine 
imaging examination of solid breast masses would there-
fore not be difficult to introduce in most breast clinics. Core 
biopsy ER status is also routinely available in nearly every 
case of both screening and symptomatic invasive cancer.
The stiffness within breast cancers at SWE is predomi-
nantly seen at the tumour/stromal boundary and in the 
peri-tumoural stroma [9, 16, 23]. This stiffness appears to 
be due to the nature of the collagen produced by tumour-
associated stromal cells (fibroblasts and cancer-associated 
fibroblasts (CAFs)) [25]. An increase in stromal stiff-
ness induces activation of the CAFs into myofibroblasts 
expressing aSMA [26] and SNAIL1 [27] resulting in 
higher contractibility capacities and maintenance of ECM 
protein secretion that further contributes to tissue stiffen-
ing. Indeed, CAFs have been shown in vitro to cause an 
eightfold increase in matrix stiffness compared with nor-
mal fibroblasts through the production of thicker collagen 
and increased collagen cross linking by lysyl oxidase [27, 
28]. This process results in the release of active TGFb 
which also maintains CAFs into their active form [29].
As well as being a risk factor for breast cancer develop-
ment, stiffening of the tumour stroma has been shown to 
enhance several key functions of tumour development. It 
does so by triggering mechano-responses of the tumour 
cells through mechano-sensors such as integrins [30]. 
More particularly, in vivo and in vitro breast models have 
shown that activation of the focal adhesion kinase (FAK), 
in response to stiff tissue, promotes tumour cell prolifera-
tion and an invasive phenotype [31]. Moreover, perpen-
dicular orientation of the collagen bundles to the primary 
lesion observed in stiff tissue allows tumour cells migra-
tion towards blood vessels as well as myeloid cell infiltra-
tion [14]. Tumour cell dissemination is also encouraged by 
the increased vascularisation which develops in response 
to stiffness-associated hypoxia. Stiff ECM also induces 
drug resistance by limiting therapeutic agent diffusion and 
by activating cellular pathways involved in tumour cell 
survival [11].
This non-exhaustive list of the pro-tumoural effects of 
stiff stroma surrounding breast tumour cells provides clues 
as to why stiff tissue measurement by shear wave elastogra-
phy is a prognostic marker of breast cancer patient survival.
Breast MRI, particularly diffusion-weighted imaging has 
been shown to correlate both with prognostic factors such 
as tumour size, histological grade and nodal positivity [32, 
33] and in combination with other imaging parameters may 
improve pre-operative prognostication.
Core biopsy ER status is routinely used to guide deci-
sions regarding pre-operative therapy and is preferred by 
Table 2  Results of univariable and multivariable analyses of pre-operative prognostic markers
Univariable model Multivariable model Final multivariable model
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Stiffness
 Tertile 2 vs 1 4.9 1.4–17 0.013 2.7 0.76–9.8 0.12 3.4 0.95–12 0.06
 Tertile 3 vs 1 8.2 2.5–27 0.0006 4 1.2–14 0.028 4.7 1.4–16 0.013
Size
 20+  mm vs < 20 mm 5.4 2.8–11 8 × 10− 7 2.8 1.4–5.7 0.0023 3.5 1.8–7.0 0.00033
 Core grade 3.9 2.1–7.2 2 × 10− 5 1.8 0.83–3.8 0.14
 Pre-op node positive 2.9 1.5–5.6 0.0014 1.8 0.90–3.6 0.096 2 1.0–3.9 0.047
 ER positive 0.21 0.11–0.38 4 × 10− 7 0.31 0.15–0.63 0.0014 0.23 0.13–0.43 3 × 10− 6
 Screen vs clinical detection 5.1 2.0–13 0.00065 1.7 0.64–4.7 0.28
 HER-2 1.3 0.55.–3.11 0.55 0.63 0.26–1.5 0.31
 Breast Cancer Research and Treatment
1 3
many to ER status derived from the surgical specimen due 
better fixation of the small sample.
The four factors found to be independently significant 
are therefore based on the biology of the tumour (ER 
status), the tumour microenvironment (stiffness) and the 
time-dependent variables of lesion size (as measured by 
ultrasound) and pre-operative nodal status.
Lymph node status is, historically, the most powerful 
of the classical prognostic factors [1] but pre-operative 
nodal status was only weakly independently significant in 
this study. While US size and stiffness have been previ-
ously shown to have independent associations with nodal 
positivity, the present model reflects the cancer biology 
(of the tumour and the microenvironment) upon which the 
traditional anatomical TNM size-based criteria (including 
tumour size and node status) are predicated. The current 
debate regarding the need for surgical treatment of the 
positive axilla means aggressive pre-operative diagnosis 
of positive axillae is not welcomed by some surgeons and 
oncologists [7]. Therefore, having a prognostic model 
which is not heavily reliant on axillary staging may be seen 
by some as advantageous. The combination of diffusion-
weighted MR imaging with morphological and dynamic 
MR imaging findings might be used in the future for differ-
entiation of metastatic from benign axillary lymph nodes 
without the need for biopsy [34].
The current study was carried out in a single centre 
with a longstanding research interest in SWE. However, 
SWE is an easy technique to learn and has been shown 
to have excellent reproducibility [14] and is in use glob-
ally. Clearly, before a practice change can be adopted into 
routine clinical practice, the findings of this study require 
confirmation in an independent series with prospective 
validation.
In conclusion, we have found that US size, stiffness, 
ER status and pre-operative nodal status are pre-operative 
factors which have independent prognostic significance 
for breast cancer-specific survival. Given larger numbers 
and longer follow-up, a simple, practical model could be 
constructed and used to assess the appropriateness of neo-
adjuvant systemic therapy and inform patients who wish to 
know prognostic information prior to surgery.
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